Details for Patent: 7,713,999

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,713,999 protect, and when does it expire?

Patent 7,713,999 protects ZONTIVITY and is included in one NDA.

This patent has one hundred and sixty-four patent family members in thirty-seven countries.

Summary for Patent: 7,713,999

Title:	Thrombin receptor antagonists
Abstract:	Heterocyclic-substituted tricyclics of the formula ##STR00001## or a pharmaceutically acceptable salt thereof, wherein: the dotted line represents an optional single bond; represents an optional double bond, n is 0-2; Q is cycloalkyl, optionally substituted by R.sup.13 and R.sup.14; R.sup.13 and R.sup.14 are independently selected from (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.8)cycloalkyl, --OH, (C.sub.1-C.sub.6)alkoxy, R.sup.27-aryl(C.sub.1-C.sub.6)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; or R.sup.13 and R.sup.14 together form a spirocyclic or a heterospirocyclic ring of 3-6 atoms, Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
Inventor(s):	Chackalamannil; Samuel (Califon, NJ), Clasby; Martin C. (Plainsboro, NJ), Greenlee; William J. (Teaneck, NJ), Wang; Yuguang (North Brunswick, NJ), Xia; Yan (Edison, NJ), Veltri; Enrico P. (Princeton, NJ), Chelliah; Mariappan V. (Edison, NJ)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	11/733,635
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 7,713,999

Glossary

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Xspire Pharma	ZONTIVITY	vorapaxar sulfate	TABLET;ORAL	204886-001	May 8, 2014		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing	Y	Y		REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION (MI) OR WITH PERIPHERAL ARTERIAL DISEASE (PAD)	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 7,713,999

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	028952	See Plans and Pricing
Argentina	039570	See Plans and Pricing
Argentina	045809	See Plans and Pricing
Argentina	047088	See Plans and Pricing
Argentina	098260	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.